Structural Basis of Analog Specificity in PKG I and II

Overview

Journal ACS Chem Biol

Publisher American Chemical Society

Specialties Biochemistry
Biology

Date 2017 Aug 10

PMID 28793191

Citations 6

Authors

James C Campbell

Philipp Henning

Eugen Franz

Banumathi Sankaran

Friedrich W Herberg

Choel Kim

Affiliations

Soon will be listed here.

Abstract

Cyclic GMP analogs, 8-Br, 8-pCPT, and PET-cGMP, have been widely used for characterizing cellular functions of cGMP-dependent protein kinase (PKG) I and II isotypes. However, interpreting results obtained using these analogs has been difficult due to their low isotype specificity. Additionally, each isotype has two binding sites with different cGMP affinities and analog selectivities, making understanding the molecular basis for isotype specificity of these compounds even more challenging. To determine isotype specificity of cGMP analogs and their structural basis, we generated the full-length regulatory domains of PKG I and II isotypes with each binding site disabled, determined their affinities for these analogs, and obtained cocrystal structures of both isotypes bound with cGMP analogs. Our affinity and activation measurements show that PET-cGMP is most selective for PKG I, whereas 8-pCPT-cGMP is most selective for PKG II. Our structures of cyclic nucleotide binding (CNB) domains reveal that the B site of PKG I is more open and forms a unique π/π interaction through Arg285 at β4 with the PET moiety, whereas the A site of PKG II has a larger β5/β6 pocket that can better accommodate the bulky 8-pCPT moiety. Our structural and functional results explain the selectivity of these analogs for each PKG isotype and provide a starting point for the rational design of isotype selective activators.

Citing Articles

Identifying therapeutic drug targets using bidirectional effect genes.

Estrada K, Froelich S, Wuster A, Bauer C, Sterling T, Clark W Nat Commun. 2021; 12(1):2224.

PMID: 33850126 PMC: 8044152. DOI: 10.1038/s41467-021-21843-8.

Cyclic nucleotide selectivity of protein kinase G isozymes.

Kim C, Sharma R Protein Sci. 2020; 30(2):316-327.

PMID: 33271627 PMC: 7784742. DOI: 10.1002/pro.4008.

Structural basis for selective inhibition of human PKG Iα by the balanol-like compound N46.

Qin L, Sankaran B, Aminzai S, Casteel D, Kim C J Biol Chem. 2018; 293(28):10985-10992.

PMID: 29769318 PMC: 6052212. DOI: 10.1074/jbc.RA118.002427.

Neutron Crystallography Detects Differences in Protein Dynamics: Structure of the PKG II Cyclic Nucleotide Binding Domain in Complex with an Activator.

Gerlits O, Campbell J, Blakeley M, Kim C, Kovalevsky A Biochemistry. 2018; 57(12):1833-1837.

PMID: 29517905 PMC: 5890435. DOI: 10.1021/acs.biochem.8b00010.

New cGMP analogues restrain proliferation and migration of melanoma cells.

Vighi E, Rentsch A, Henning P, Comitato A, Hoffmann D, Bertinetti D Oncotarget. 2018; 9(4):5301-5320.

PMID: 29435180 PMC: 5797051. DOI: 10.18632/oncotarget.23685.

References

Qin L, Reger A, Guo E, Yang M, Zwart P, Casteel D . Structures of cGMP-Dependent Protein Kinase (PKG) Iα Leucine Zippers Reveal an Interchain Disulfide Bond Important for Dimer Stability. Biochemistry. 2015; 54(29):4419-22. PMC: 4838416. DOI: 10.1021/acs.biochem.5b00572. View

Schlossmann J, Hofmann F . cGMP-dependent protein kinases in drug discovery. Drug Discov Today. 2005; 10(9):627-34. DOI: 10.1016/S1359-6446(05)03406-9. View

Valtcheva N, Nestorov P, Beck A, Russwurm M, Hillenbrand M, Weinmeister P . The commonly used cGMP-dependent protein kinase type I (cGKI) inhibitor Rp-8-Br-PET-cGMPS can activate cGKI in vitro and in intact cells. J Biol Chem. 2008; 284(1):556-562. DOI: 10.1074/jbc.M806161200. View

Rehmann H, Wittinghofer A, Bos J . Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol. 2006; 8(1):63-73. DOI: 10.1038/nrm2082. View

Casteel D, Smith-Nguyen E, Sankaran B, Roh S, Pilz R, Kim C . A crystal structure of the cyclic GMP-dependent protein kinase I{beta} dimerization/docking domain reveals molecular details of isoform-specific anchoring. J Biol Chem. 2010; 285(43):32684-32688. PMC: 2963381. DOI: 10.1074/jbc.C110.161430. View

Gloeckner C, Boldt K, Schumacher A, Roepman R, Ueffing M . A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics. 2007; 7(23):4228-34. DOI: 10.1002/pmic.200700038. View

Hofmann F, Wegener J . cGMP-dependent protein kinases (cGK). Methods Mol Biol. 2013; 1020:17-50. DOI: 10.1007/978-1-62703-459-3_2. View

Zhang P, Smith-Nguyen E, Keshwani M, Deal M, Kornev A, Taylor S . Structure and allostery of the PKA RIIβ tetrameric holoenzyme. Science. 2012; 335(6069):712-6. PMC: 3985767. DOI: 10.1126/science.1213979. View

Pohler D, Butt E, Meissner J, Muller S, Lohse M, Walter U . Expression, purification, and characterization of the cGMP-dependent protein kinases I beta and II using the baculovirus system. FEBS Lett. 1995; 374(3):419-25. DOI: 10.1016/0014-5793(95)01168-e. View

10.

Johannessen C, Boehm J, Kim S, Thomas S, Wardwell L, Johnson L . COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468(7326):968-72. PMC: 3058384. DOI: 10.1038/nature09627. View

11.

Francis S, Busch J, Corbin J, Sibley D . cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010; 62(3):525-63. PMC: 2964902. DOI: 10.1124/pr.110.002907. View

12.

Hofmann F, Feil R, Kleppisch T, Schlossmann J . Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev. 2005; 86(1):1-23. DOI: 10.1152/physrev.00015.2005. View

13.

STEINBERG R, Gorman K, Ogreid D, Doskeland S, Weber I . Mutations that alter the charge of type I regulatory subunit and modify activation properties of cyclic AMP-dependent protein kinase from S49 mouse lymphoma cells. J Biol Chem. 1991; 266(6):3547-53. View

14.

Campbell J, Kim J, Li K, Huang G, Reger A, Matsuda S . Structural Basis of Cyclic Nucleotide Selectivity in cGMP-dependent Protein Kinase II. J Biol Chem. 2016; 291(11):5623-5633. PMC: 4786703. DOI: 10.1074/jbc.M115.691303. View

15.

Schwede F, Maronde E, Genieser H, Jastorff B . Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther. 2000; 87(2-3):199-226. DOI: 10.1016/s0163-7258(00)00051-6. View

16.

Moll D, Prinz A, Gesellchen F, Drewianka S, Zimmermann B, Herberg F . Biomolecular interaction analysis in functional proteomics. J Neural Transm (Vienna). 2006; 113(8):1015-32. DOI: 10.1007/s00702-006-0515-5. View

17.

Reger A, Yang M, Koide-Yoshida S, Guo E, Mehta S, Yuasa K . Crystal structure of the cGMP-dependent protein kinase II leucine zipper and Rab11b protein complex reveals molecular details of G-kinase-specific interactions. J Biol Chem. 2014; 289(37):25393-403. PMC: 4162144. DOI: 10.1074/jbc.M114.575894. View

18.

Kim J, Casteel D, Huang G, Kwon T, Ren R, Zwart P . Co-crystal structures of PKG Iβ (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding. PLoS One. 2011; 6(4):e18413. PMC: 3080414. DOI: 10.1371/journal.pone.0018413. View

19.

Corbin J, Ogreid D, Miller J, Suva R, Jastorff B, Doskeland S . Studies of cGMP analog specificity and function of the two intrasubunit binding sites of cGMP-dependent protein kinase. J Biol Chem. 1986; 261(3):1208-14. View

20.

Vaandrager A, Edixhoven M, Bot A, Kroos M, Jarchau T, Lohmann S . Endogenous type II cGMP-dependent protein kinase exists as a dimer in membranes and can Be functionally distinguished from the type I isoforms. J Biol Chem. 1997; 272(18):11816-23. DOI: 10.1074/jbc.272.18.11816. View